Barclays analyst Mathieu Robilliard lowered the firm’s price target on Iridium (IRDM) to $31 from $38 and keeps an Overweight rating on the shares. The firm reduced estimates post earnings to reflect less certain growth opportunities in Iridium’s new verticals. However, the firm believes the company’s growth remains attractive and the stock’s valuation is supportive.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRDM:
- CRSP, ABSI, IRDM: Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Buys Absci and Iridium
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Cathie Wood Bets Big on This Satellite Stock, Exits COIN and RBLX Positions
- Iridium price target lowered to $39 from $47 at Raymond James
- Iridium Communications Reports Q2 2025 Earnings and Outlook